Bailey (MB102014) 2010

NCT00528879

1 Treatments

Studied treatment dapagliflozin (2.5 mg, n=137; 5 mg, n=137; or 10 mg, n=135)

Control treatment placebo

Concomittant treatments daily metformin (≥1500 mg per day)

2 Patients

Patients adults with type 2 diabetes who were receiving daily metformin (≥1500 mg per day) and had inadequate glycaemic control

Inclusion criteria -

Exclusion criteria -

3 Methods

Blinding double-blind

Design Parallel groups

Centers -

Geographical area -

Sizes -9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>MI</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all cause deaths</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV events</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV deaths</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>stroke</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References


